Straining Rachael, Eighmy William
Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut.
J Adv Pract Oncol. 2022 Mar;13(2):158-163. doi: 10.6004/jadpro.2022.13.2.7. Epub 2022 Mar 25.
Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 () is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that specifically inhibits EZH2. This new FDA-approved oral treatment received accelerated approval for patients with hematologic and solid malignancies. Tazemetostat was first approved for patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection based on the results of an international open-label phase II basket trial. Another open-label multicenter phase II trial led to the approval for patients with relapsed or refractory follicular lymphoma with mutation who have received at least two prior systemic therapies or patients who have no satisfactory alternative treatment options. Tazemetostat as an oral EZH2 inhibitor provides a new effective and tolerable treatment option for these patients.
表观遗传调控是一种新型的癌症治疗方法。抑制zeste同源物2（EZH2）是一种实现靶向表观遗传调控的方法。他泽司他是首个获批的靶向表观遗传调节剂，可特异性抑制EZH2。这种新的经美国食品药品监督管理局（FDA）批准的口服治疗药物已获得加速批准，用于治疗血液系统恶性肿瘤和实体恶性肿瘤患者。基于一项国际开放标签II期篮子试验的结果，他泽司他首次获批用于治疗16岁及以上无法进行完全切除的转移性或局部晚期上皮样肉瘤患者。另一项开放标签多中心II期试验促使其获批用于治疗携带 突变、既往至少接受过两种全身治疗的复发或难治性滤泡性淋巴瘤患者，或没有满意替代治疗方案的患者。他泽司他作为一种口服EZH2抑制剂，为这些患者提供了一种新的有效且耐受性良好的治疗选择。
